Literature DB >> 28280624

The concept of 'borderline resectable' pancreatic cancer: limited foundations and limited future?

John A Windsor1, Savio George Barreto2.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is traditionally treated by a surgery-first approach. The development and adoption of the concept of borderline resectable PDAC, which extends the role of surgery, is based on the proposition that neoadjuvant therapy (NAT) will increase the resection rate, margin negative rate and overall survival. There are a number of issues with this concept and a critical review of these suggests that it is based on limited foundations and likely has a limited future.

Entities:  

Keywords:  Morbidity; mortality; outcomes; research; survival

Year:  2017        PMID： 28280624      PMCID： PMC5334050          DOI： 10.21037/jgo.2016.12.06

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN： 2078-6891


  40 in total

1.  1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience.

Authors:  Jordan M Winter; John L Cameron; Kurtis A Campbell; Meghan A Arnold; David C Chang; Joann Coleman; Mary B Hodgin; Patricia K Sauter; Ralph H Hruban; Taylor S Riall; Richard D Schulick; Michael A Choti; Keith D Lillemoe; Charles J Yeo
Journal:  J Gastrointest Surg       Date:  2006-11       Impact factor: 3.452

2.  Staging and extended resection for pancreatic cancer.

Authors:  T Naganuma; S Isaji; Y Kawarada
Journal:  Pancreas       Date:  1998-04       Impact factor: 3.327

3.  Justifying vein resection with pancreatoduodenectomy - Author's reply.

Authors:  Savio G Barreto; John A Windsor
Journal:  Lancet Oncol       Date:  2016-04-27       Impact factor: 41.316

4.  Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas.

Authors:  J F Pingpank; J P Hoffman; E A Ross; H S Cooper; N J Meropol; G Freedman; W H Pinover; T E LeVoyer; A R Sasson; B L Eisenberg
Journal:  J Gastrointest Surg       Date:  2001 Mar-Apr       Impact factor: 3.452

5.  Clinical significance of portal-superior mesenteric vein resection in pancreatoduodenectomy for pancreatic head cancer.

Authors:  Sung-Sik Han; Sang-Jae Park; Seong Hoon Kim; Seong Yeon Cho; Young-Kyu Kim; Tae Hyun Kim; Soon-ae Lee; Sang Myung Woo; Woo Jin Lee; Eun Kyung Hong
Journal:  Pancreas       Date:  2012-01       Impact factor: 3.327

Review 6.  Approach to patients with pancreatic cancer without detectable metastases.

Authors:  Gregory M Heestand; James D Murphy; Andrew M Lowy
Journal:  J Clin Oncol       Date:  2015-04-27       Impact factor: 44.544

Review 7.  Molecular classification of neoplasms of the pancreas.

Authors:  Ralph H Hruban; N Volkan Adsay
Journal:  Hum Pathol       Date:  2009-05       Impact factor: 3.466

8.  National patterns of care for pancreatic cancer. Results of a survey by the Commission on Cancer.

Authors:  R H Janes; J E Niederhuber; J S Chmiel; D P Winchester; K C Ocwieja; J H Karnell; R E Clive; H R Menck
Journal:  Ann Surg       Date:  1996-03       Impact factor: 12.969

Review 9.  Meta-analysis of benefits of portal-superior mesenteric vein resection in pancreatic resection for ductal adenocarcinoma.

Authors:  F Giovinazzo; G Turri; M H Katz; N Heaton; I Ahmed
Journal:  Br J Surg       Date:  2015-12-10       Impact factor: 6.939

Review 10.  Neoadjuvant therapy in pancreatic cancer: an emerging strategy.

Authors:  Alessandro Bittoni; Matteo Santoni; Andrea Lanese; Chiara Pellei; Kalliopi Andrikou; Cascinu Stefano
Journal:  Gastroenterol Res Pract       Date:  2014-07-01       Impact factor: 2.260
View more
  1 in total

Review 1.  Role of imaging in evaluating the response after neoadjuvant treatment for pancreatic ductal adenocarcinoma.

Authors:  Yun Zhang; Zi-Xing Huang; Bin Song
Journal:  World J Gastroenterol       Date:  2021-06-14       Impact factor: 5.742
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.